CAR T-Cell Therapy in Multiple Myeloma: CCO Independent Conference Updates From IMS 2024

Emerging data presented at the annual IMS meeting 2024 are discussed. Find out how CAR T-cell therapy can be used as an individualized therapeutic strategy for patients with multiple myeloma.

Share

Program Content

Activities

Advances in CAR T Cell Tx for MM
Independent Conference Highlights From IMS 2024: Recent Advances in CAR T-Cell Therapies for Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 01, 2024

Expires: April 30, 2025

Faculty

cover img faculity

Nikhil Munshi, MD

Professor of Medicine
Harvard Medical School
Kraft Family Chair
Director, Basic and Correlative Sciences & Associate Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC